IP Library Granted Patent US 8,106,351
Granted Patent B2
US 8,106,351 · App. 12/715,343 · Granted Jan 31, 2012

Mass spectrometry assay for plasma-renin

Assignee: Quest Diagnostics Investments Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,106,351
App. No.
12/715,343
Granted
Jan 31, 2012
Kind
B2
Abstract

Provided are methods for measuring renin activity in a plasma sample using mass spectrometry. The methods generally involve ionizing purified angiotensin 1 from the sample and detecting the amount of angiotensin 1 ions generated. The amount of detected angiotensin 1 ions are then related to the amount of angiotensin 1 generated in the sample, which in turn is related to renin activity in the sample.

Claims (56)

1. A method for measuring the amount of angiotensin 1 in a sample, said method comprising:

(a) ionizing angiotensin 1 from said sample to produce a precursor ion detectable by mass spectrometry wherein said precursor ion has a mass to charge ratio of 433.0±0.5;

(b) fragmenting said precursor ion to produce a fragment ion with a mass/charge ratio of 619.5±0.5;

(c) detecting the amount of one or more of the precursor and fragment ions by mass spectrometry; and

(d) using the amount of ion(s) detected to measure the amount of angiotensin 1 in said sample.

2. The method of claim 1 , wherein said method has a limit of quantitation less than or equal to 0.1 ng/mL.

3. The method of claim 1 , wherein said method further comprises purifying angiotensin 1 from said sample by high performance liquid chromatography (HPLC).

4. The method of claim 1 , wherein said method further comprises purifying angiotensin 1 from said sample with a solid-phase extraction column.

5. The method of claim 1 , wherein the amount of the angiotensin 1 ion is related to the presence or amount of angiotensin 1 in the sample by comparison to an internal standard.

6. A method for determining whether a patient exhibiting low plasma renin activity levels as determined by the method of claim 1 is a member of a subpopulation with high natural degradation of angiotensin 1, said method comprising: measuring the degree of degradation of angiotensin 1 in the sample by adding a degradation standard to the sample prior to incubation and measuring the amount of degradation standard remaining after incubation.

7. A method for measuring the amount of angiotensin 1 in a sample, said method comprising:

(a) incubating said sample premixed with water stable protease inhibitor that is not effective against renin under conditions suitable for the generation of angiotensin 1 by renin in the sample;

(b) purifying angiotensin 1 in said sample by liquid chromatography;

(c) ionizing the purified angiotensin 1 from said sample to produce one or more ions detectable by mass spectrometry;

(d) detecting the amount of the angiotensin 1 ion(s) by mass spectrometry; and

(e) using the amount of ion(s) detected to measure the amount of angiotensin 1 in said sample.

8. The method of claim 7 , wherein said method has a limit of quantitation less than or equal to 0.1 ng/mL.

9. The method of claim 7 , wherein said angiotensin 1 ions comprise an ion with a mass/charge ratio of 619.5±0.5.

10. The method of claim 7 , wherein said ionizing comprises generating a precursor ion with a mass/charge ratio of 433.0±0.5, and generating a fragment ion with a mass/charge ratio of 619.5±0.5.

11. The method of claim 7 , wherein the amount of the angiotensin 1 ion is related to the presence or amount of angiotensin 1 in the sample by comparison to an internal standard.

12. The method of claim 7 , wherein said step (b) comprises purifying angiotensin 1 from said sample with a solid-phase extraction column.

13. The method of claim 7 , wherein said water stable protease inhibitor is aminoethylbenzylsulfonyl fluoride.

14. The method of claim 7 , further comprising measuring the degree of degradation of angiotensin 1 in the sample by adding a degradation standard to the sample prior to incubation and measuring the amount of degradation standard remaining after incubation.

15. The method of claim 7 , further comprising measuring the degree of degradation of angiotensin 1 in the sample by adding a degradation standard to the sample prior to incubation and measuring the amount of breakdown products from degradation of the degradation standard in the sample after incubation.

16. A method for measuring renin activity in a sample, said method comprising,

(a) incubating the sample premixed with a water stable protease inhibitor that is not effective against renin under conditions suitable for the generation of angiotensin 1 by renin in the sample;

(b) purifying angiotensin 1 by liquid chromatography;

(c) ionizing the purified angiotensin 1 from said sample to produce one or more ions detectable by mass spectrometry;

(d) detecting the amount of the angiotensin 1 ion(s) by mass spectrometry;

(e) using the amount of ion(s) detected to measure the amount of angiotensin 1 in said sample; and

(f) using the amount of angiotensin 1 measured in said sample to calculate renin activity in the sample.

17. The method of claim 16 , wherein said liquid chromatography is high performance liquid chromatography (HPLC).

18. The method of claim 16 , wherein said method has a limit of quantitation less than or equal to 0.1 ng/mL.

19. The method of claim 16 , wherein said angiotensin 1 ions comprise an ion with a mass/charge ratio of 619.5±0.5.

20. The method of claim 16 , wherein said ionizing comprises generating a precursor ion with a mass/charge ratio of 433.0±0.5, and generating a fragment ion with a mass/charge ratio of 619.5±0.5.

21. The method of claim 16 , wherein said purifying angiotensin 1 in step (b) comprises purifying angiotensin 1 with a solid-phase extraction column.

22. The method of claim 16 , wherein said water stable protease inhibitor is aminoethylbenzylsulfonyl fluoride.

23. The method of claim 16 , wherein the presence or amount of the angiotensin 1 ion is related to the presence or amount of angiotensin 1 in the sample by comparison to an internal standard.

24. The method of claim 16 , further comprising measuring the degree of degradation of angiotensin 1 in the sample by adding a degradation standard to the sample prior to incubation and measuring the amount of degradation standard remaining after incubation.

25. The method of claim 16 , further comprising measuring the degree of degradation of angiotensin 1 in the sample by adding a degradation standard to the sample prior to incubation and measuring the amount of breakdown products from degradation of the degradation standard in the sample after incubation.

26. A method for measuring renin activity in a sample, said method comprising,

(a) incubating the sample under conditions suitable for the generation of angiotensin 1 by renin in the sample;

(b) purifying angiotensin 1 in said sample by liquid chromatography;

(c) ionizing the purified angiotensin 1 from said sample to produce one or more ions detectable by mass spectrometry;

(d) detecting the amount of the angiotensin 1 ion(s) by mass spectrometry, said ions comprising an ion with a mass/charge ratio of 619.5±0.5; and

(e) using the amount of ion(s) detected to measure the amount of angiotensin 1 in said sample; and

(f) using the amount of angiotensin 1 measured in said sample to calculate renin activity in the sample.

27. The method of claim 26 , wherein said ionizing comprises generating a precursor ion with a mass/charge ratio of 433.0±0.5, and generating a fragment ion with a mass/charge ratio of 619.5±0.5.

28. The method of claim 26 , wherein said method has a limit of quantitation less than or equal to 0.1 ng/mL.

29. The method of claim 26 , wherein incubating in step (a) comprises incubating in the presence of a water stable protease inhibitor that is not effective against renin.

30. The method of claim 29 , wherein said water stable protease inhibitor is aminoethylbenzylsulfonyl fluoride.

31. The method of claim 26 , wherein said purified angiotensin 1 is purified by high performance liquid chromatography (HPLC).

32. The method of claim 26 , wherein said method further comprises purifying angiotensin 1 from said sample with a solid-phase extraction column.

33. The method of claim 26 , wherein the presence or amount of the angiotensin 1 ion is related to the presence or amount of angiotensin 1 in the sample by comparison to an internal standard.

34. The method of claim 26 , further comprising measuring the degree of degradation of angiotensin 1 in the sample by adding a degradation standard to the sample prior to incubation and measuring the amount of degradation standard remaining after incubation.

35. The method of claim 26 , further comprising measuring the degree of degradation of angiotensin 1 in the sample by adding a degradation standard to the sample prior to incubation and measuring the amount of breakdown products from degradation of the degradation standard in the sample after incubation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2010
From: BYSTROM, CORY E.; REITZ, RICHARD E.; CLARKE, NIGEL J.
To: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
Reel/Frame 024396/0853 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2010
From: BYSTROM, CORY E.; REITZ, RICHARD E.; CLARKE, NIGEL J.
To: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
Reel/Frame 024389/0618 →
Continuity (1)
Related Publication 20100219338A1 · Sep 2, 2010